Search

The research objectives of this collaboration include the characterization of experimental models of AD to identity those with higher physiological relevance and disease predictability.

Don't miss us at the 51st Annual Meeting of the Japanese Society of Toxicology!

All resolutions were approved. Additional resolution to increase capital for up to 100 million euros approved. 42.6867% of the issued shares represented

The objective of this study was to review the characteristics of patients admitted with septic arthritis in Spanish hospitals and to measure the associated direct medical costs.

Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study.

Meet Lifesome Therapeutics, our new member. We talked its Diego Pazos Castro, Cancer & Microbiology Research Scientist.

The top leadership team from HERA (Health Emergency Preparedness and Response), the European Commission's authority for the prevention, detection and rapid response to health emergencies in the

Mikrobiomik is working to become the first company globally to market the first biological drug based on gut microbiota in the European Union for the indication of recurrence of 'Clostridium difficile

Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre.

The event "Challenges and Opportunities for Spain in the Application of AI in Health Data Spaces," organized by AseBio together with the Ministry of Health, brought together leading organizations from

Biotech entrepreneurs have experienced a demanding drug development environment in the last 24 months. To succeed, biotech leaders must overcome challenges associated with planning, fundraising, and

It provides an overview of the key changes that will impact access to innovative medicines and advanced therapies in the EU.

Meet ASPARIA GLYCOMICS, our new member. We talked to its Ane Rodrigo, Sales & Marketing Manager.

Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity. A third cohort is ongoing following FDA’s OPTIMUS

Meet Paralab Bio, our new member. We talked to its Andrea Zapater, Bio Product Specialist.

Private funding raised by the sector reached an all-time high, surpassing 228 million euros after a 37% increase.